| 76.3529 -0.048 (-0.06%) | 04-24 14:47 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 91.82 | 1-year : | 94.19 |
| Resists | First : | 78.61 | Second : | 80.65 |
| Pivot price | 76.8  |
|||
| Supports | First : | 75.33 | Second : | 62.67 |
| MAs | MA(5) : | 76.02 |
MA(20) : | 77.47 |
| MA(100) : | 76.61 |
MA(250) : | 75.45 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 23.3 |
D(3) : | 17.7 |
| RSI | RSI(14): 42.1 |
|||
| 52-week | High : | 80.65 | Low : | 67.75 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PJP ] has closed above bottom band by 38.2%. Bollinger Bands are 22.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 76.63 - 77.01 | 77.01 - 77.31 |
| Low: | 75.13 - 75.65 | 75.65 - 76.08 |
| Close: | 75.62 - 76.41 | 76.41 - 77.04 |
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is composed of common stocks of U.S. pharmaceutical companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.
Wed, 24 Apr 2024
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now? - Yahoo Canada Finance
Wed, 17 Apr 2024
60880 Shares in Invesco Pharmaceuticals ETF (NYSEARCA:PJP) Acquired by International Assets Investment ... - Defense World
Tue, 27 Feb 2024
PJP: Pharma Investing Is Difficult And This Fund Doesn't Make It Easier - Seeking Alpha
Thu, 18 May 2023
Want to Invest in Pharmaceutical Stocks but Don't Know How? Try This ETF. - The Motley Fool
Thu, 27 Oct 2022
3 ETFs for the Healthcare Sector’s Highs - ETF Trends
Mon, 14 Feb 2022
Top 5 Reasons behind the Biopharma Bear Market - Genetic Engineering & Biotechnology News
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|